Medpace Holdings, Inc. (MEDP) P/E Ratio History
Fairly ValuedTrading at 35.8x, near 5Y avg of 31.6x · 65th percentile · In line with own history · Data 2016–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Medpace Holdings, Inc. (MEDP) trades at a price-to-earnings ratio of 35.8x, with a stock price of $546.29 and trailing twelve-month earnings per share of $15.90.
The current P/E is 13% above its 5-year average of 31.6x. Over the past five years, MEDP's P/E has ranged from a low of 23.3x to a high of 45.2x, placing the current valuation at the 65th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, MEDP trades at a 53% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 1.12 (P/E divided by 21% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, MEDP commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MEDP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MEDP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MEDP P/E vs Peers
Contract Research and Preclinical Services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $13B | 58.2 | - | -70% | |
| $1B | 25.3 | - | -4% | |
| $8B | 70.9 | - | -4% | |
| $35B | 26.6 | 0.66Best | +5% | |
| $192B | 29.1 | 13.79 | +7% | |
| $137B | 38.5 | - | -5% | |
| $8B | 10.5Lowest | - | +143%Best | |
| $31B | 35.3 | 1.94 | +26% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MEDP Historical P/E Data (2016–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $480.19 | $15.92 | 30.2x | -26% |
| FY2025 Q4 | Dec 31 2025 | $561.65 | $15.31 | 36.7x | -10% |
| FY2025 Q3 | - | $514.16 | $14.31 | 35.9x | -12% |
| FY2025 Q2 | Jun 30 2025 | $313.86 | $13.45 | 23.3x | -43% |
| FY2025 Q1 | Mar 31 2025 | $304.69 | $13.10 | 23.3x | -43% |
| FY2024 Q4 | - | $332.23 | $12.63 | 26.3x | -35% |
| FY2024 Q3 | Sep 30 2024 | $333.80 | $11.42 | 29.2x | -28% |
| FY2024 Q2 | Jun 30 2024 | $411.85 | $10.63 | 38.7x | -5% |
| FY2024 Q1 | Mar 31 2024 | $404.15 | $9.81 | 41.2x | +1% |
| FY2023 Q4 | Dec 31 2023 | $306.53 | $8.88 | 34.5x | -15% |
| FY2023 Q3 | Sep 30 2023 | $242.13 | $8.53 | 28.4x | -30% |
| FY2023 Q2 | Jun 30 2023 | $240.17 | $8.36 | 28.7x | -29% |
| FY2023 Q1 | Mar 31 2023 | $188.05 | $7.89 | 23.8x | -41% |
| FY2022 Q4 | Dec 31 2022 | $212.41 | $7.31 | 29.1x | -28% |
| FY2022 Q3 | Sep 30 2022 | $157.17 | $6.52 | 24.1x | -41% |
| FY2022 Q2 | - | $149.67 | $5.76 | 26.0x | -36% |
| FY2022 Q1 | - | $163.59 | $5.36 | 30.5x | -25% |
| FY2021 Q4 | Dec 31 2021 | $217.64 | $4.81 | 45.2x | +11% |
| FY2021 Q3 | - | $189.28 | $4.83 | 39.2x | -4% |
| FY2021 Q2 | Jun 30 2021 | $176.63 | $4.63 | 38.1x | -6% |
| FY2021 Q1 | Mar 31 2021 | $164.05 | $4.21 | 39.0x | -4% |
| FY2020 Q4 | - | $139.20 | $3.83 | 36.3x | -11% |
| FY2020 Q3 | Sep 30 2020 | $111.75 | $3.28 | 34.1x | -16% |
| FY2020 Q2 | - | $93.02 | $2.82 | 33.0x | -19% |
| FY2020 Q1 | - | $73.38 | $2.91 | 25.2x | -38% |
| FY2019 Q4 | - | $84.06 | $2.66 | 31.6x | -22% |
| FY2019 Q3 | Sep 30 2019 | $84.04 | $2.48 | 33.9x | -17% |
| FY2019 Q2 | Jun 30 2019 | $65.42 | $2.37 | 27.6x | -32% |
| FY2019 Q1 | Mar 31 2019 | $58.97 | $2.09 | 28.2x | -31% |
| FY2018 Q4 | Dec 31 2018 | $52.93 | $1.98 | 26.7x | -34% |
| FY2018 Q3 | Sep 30 2018 | $59.91 | $1.66 | 36.1x | -11% |
| FY2018 Q2 | Jun 30 2018 | $43.00 | $1.39 | 30.9x | -24% |
| FY2018 Q1 | Mar 31 2018 | $34.91 | $1.17 | 29.8x | -27% |
| FY2017 Q4 | Dec 31 2017 | $36.26 | $0.97 | 37.4x | -8% |
| FY2017 Q3 | Sep 30 2017 | $31.90 | $0.68 | 46.9x | +16% |
| FY2017 Q2 | Jun 30 2017 | $29.00 | $0.56 | 51.8x | +28% |
| FY2017 Q1 | Mar 31 2017 | $29.85 | $0.48 | 62.3x | +53% |
| FY2016 Q4 | Dec 31 2016 | $36.07 | $0.39 | 92.6x | +128% |
| FY2016 Q3 | Sep 30 2016 | $29.86 | $0.12 | 248.8x | +512% |
Average P/E for displayed period: 40.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MEDP — Frequently Asked Questions
Quick answers to the most common questions about buying MEDP stock.
What is MEDP's P/E ratio?
Medpace Holdings, Inc. (MEDP) trailing twelve-month P/E ratio is 35.8x, based on TTM diluted EPS of $15.90. The 5-year average P/E is 31.6x and the historical range spans 23.3x to 45.2x.
Is MEDP stock overvalued or undervalued?
MEDP trades at 35.8x P/E, near its 5-year average of 31.6x. The 65th percentile ranking within the 23.3x–45.2x historical range places valuation within normal bounds.
Is MEDP stock expensive?
MEDP is fairly valued relative to its own history. The current P/E of 35.8x is near the 5-year average of 31.6x (65th percentile of historical range).
What is MEDP's historical P/E range?
Over the past 5 years, MEDP's P/E ratio has ranged from 23.3x to 45.2x, with a median of 30.2x and an average of 31.6x. The current P/E of 35.8x places the stock at the 65th percentile of this range. Full historical data spans 2016–2026.
How does MEDP's P/E compare to the S&P 500?
MEDP trades at 35.8x P/E versus the S&P 500 median of 25.9x. The 38% premium to the market typically reflects higher expected earnings growth or quality.
How does MEDP's valuation compare to Healthcare peers?
Medpace Holdings, Inc. P/E of 35.8x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MEDP's PEG ratio?
MEDP PEG ratio is 1.12, based on a P/E of 35.8x and EPS growth of 21.0%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is MEDP's earnings yield?
MEDP earnings yield is 2.80%, the inverse of its 35.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.